Corcept (CORT) CDO sells 20K shares under 10b5-1 plan – Stock Titan
SoundHound AI Reports Record Q1 Revenue of $44.2 Million, Up 52%
The Trade Desk Reports First Quarter 2026 Financial Results
Applied Optoelectronics Reports First Quarter 2026 Results
CoreWeave Reports Strong First Quarter 2026 Results
SMX Announces Effective Date of Reverse Stock Split
MercadoLibre, Inc. Reports First Quarter 2026 Financial Results
SoundHound AI Reports Record Q1 Revenue of $44.2 Million, Up 52%
The Trade Desk Reports First Quarter 2026 Financial Results
Applied Optoelectronics Reports First Quarter 2026 Results
CoreWeave Reports Strong First Quarter 2026 Results
SMX Announces Effective Date of Reverse Stock Split
MercadoLibre, Inc. Reports First Quarter 2026 Financial Results
Corcept Therapeutics’ Chief Development Officer William Guyer exercised stock options and sold shares on May 5, 2026. He exercised options to acquire 20,000 shares of common stock at $21.65 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $51.83 per share, with actual prices ranging from $51.60 to $52.05. Following these transactions, he directly holds 2,231 common shares, which include 224 and 498 shares underlying unvested restricted stock awards that each vest in full one year after their respective grant dates if conditions are met. He also holds 170,000 fully exercisable stock options with a $21.65 exercise price expiring on September 1, 2031. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024.
Source: View Original Filing on SEC EDGAR
© 2020-2026 StockTitan.net – Your Edge is Information
Information only. Not investment advice.
source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.
